Armata Pharmaceuticals Inc
NYSE-MKT:ARMP
Armata Pharmaceuticals Inc
NYSE-MKT:ARMP
Price:
2.65 USD
-9.25%
Updated:
May 16, 2024
Section:
Relative Value
The Relative Value of one
ARMP
stock under the Base Case scenario is
1.91
USD.
Compared to the current market price of 2.65 USD,
Armata Pharmaceuticals Inc
is
Overvalued by 28%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARMP
Relative Value
Base Case
1.91
USD
Overvaluation 28%
Valuation Multiples
Multiples Across Competitors
ARMP Competitors Multiples
Armata Pharmaceuticals Inc Competitors
Armata Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Armata Pharmaceuticals Inc
NYSE-MKT:ARMP
|
95.8m USD | 20.4 | -1.2 | -3.9 | -3.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 5.3 | 60 | 13 | 19.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 5.8 | 45.5 | 19.1 | 31.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 11.4 | 31.1 | 25.2 | 26.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 8.2 | 27.9 | 22.6 | 25.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
138.6B AUD | 6.6 | 37.6 | 22.6 | 28.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.5B USD | 3 | 172.5 | 6.9 | 9.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.4B USD | 9.6 | -8.3 | -9.1 | -8.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
34.3B USD | 3.5 | 29.4 | 14.9 | 18.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.4 | 74.7 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
